Holly J Meany1, Nita L Seibel, Mark Krailo, Doojduen Villaluna, Zhengjia Chen, Paul Gaynon, Joseph P Neglia, Julie R Park, Raymond Hutchinson, Judith K Sato, Robert J Wells, William G Woods, Gregory Reaman. 1. *Department of Pediatric Hematology-Oncology, Children's National Medical Center, George Washington University School of Medicine and Public Health, Washington, DC †Clinical Investigations Branch, Cancer Therapy Evaluation Program, NCI, Bethesda ¶¶Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD ‡Keck School of Medicine, University of Southern California ¶Division of Hematology-Oncology, Children's Hospital Los Angeles, Los Angeles §Children's Oncology Group, Arcadia ‡‡Department of Pediatrics, City of Hope National Medical Center, Duarte, CA ∥Department of Biostatistics and Bioinformatics, Emory University ∥∥Aflac Cancer and Blood Disorder Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA #Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN **Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA ††Pediatric Hematology-Oncology, C.S. Mott Children's Hospital, Ann Arbor, MI §§Division of Pediatrics, Children's Cancer Hospital at the University of Texas M.D. Anderson Cancer Center, Houston, TX.
Abstract
BACKGROUND: B43-pokeweed antiviral protein (B43-PAP) is a high-affinity anti-CD19 immunotoxin that is capable of causing apoptotic death in B-lineage leukemic cells with a drug-resistant phenotype. B43-PAP exhibited in vivo antileukemic activity in preclinical studies as well as on a single-agent phase I clinical trial. This pediatric phase I/II study evaluated the toxicity profile and efficacy of B43-PAP immunotoxin in combination with standard induction chemotherapy in children and adolescents with relapsed CD19-positive B-lineage acute lymphoblastic leukemia (B-ALL). Pharmacokinetic profile and immunogenicity of B43-PAP were assessed. EXPERIMENTAL DESIGN: B43-PAP in combination with standard 3 and 4-drug induction chemotherapy was administered on days 9-13 and 21-25 of a 28-day treatment course with vincristine, prednisone, L-asparaginase, daunomycin, and intrathecal methotrexate. Thirty patients with relapsed B-ALL were enrolled on study CCG-0957. RESULTS: Grade III/IV nonhematologic dose-limiting toxicities were encountered in 4 patients evaluable for toxicity and included myalgias, motor dysfunction, pulmonary toxicity, and elevated liver transaminase. Dose-limiting toxicities occurred only with the 4-drug regimen. Fourteen patients achieved a complete remission at the end of induction among the 20 patients evaluable for response. CONCLUSIONS: B43-PAP in combination with standard induction chemotherapy can be safely administered and exhibits clinical antileukemic activity against relapsed B-ALL.
BACKGROUND: B43-pokeweed antiviral protein (B43-PAP) is a high-affinity anti-CD19 immunotoxin that is capable of causing apoptotic death in B-lineage leukemic cells with a drug-resistant phenotype. B43-PAP exhibited in vivo antileukemic activity in preclinical studies as well as on a single-agent phase I clinical trial. This pediatric phase I/II study evaluated the toxicity profile and efficacy of B43-PAP immunotoxin in combination with standard induction chemotherapy in children and adolescents with relapsed CD19-positive B-lineage acute lymphoblastic leukemia (B-ALL). Pharmacokinetic profile and immunogenicity of B43-PAP were assessed. EXPERIMENTAL DESIGN:B43-PAP in combination with standard 3 and 4-drug induction chemotherapy was administered on days 9-13 and 21-25 of a 28-day treatment course with vincristine, prednisone, L-asparaginase, daunomycin, and intrathecal methotrexate. Thirty patients with relapsed B-ALL were enrolled on study CCG-0957. RESULTS: Grade III/IV nonhematologic dose-limiting toxicities were encountered in 4 patients evaluable for toxicity and included myalgias, motor dysfunction, pulmonary toxicity, and elevated liver transaminase. Dose-limiting toxicities occurred only with the 4-drug regimen. Fourteen patients achieved a complete remission at the end of induction among the 20 patients evaluable for response. CONCLUSIONS:B43-PAP in combination with standard induction chemotherapy can be safely administered and exhibits clinical antileukemic activity against relapsed B-ALL.
Authors: L Pasqualucci; L Flenghi; A Terenzi; A Bolognesi; F Stirpe; B Bigerna; B Falini Journal: Haematologica Date: 1995 Nov-Dec Impact factor: 9.941
Authors: Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp Journal: N Engl J Med Date: 2014-10-16 Impact factor: 91.245
Authors: F M Uckun; J B Nachman; H N Sather; M G Sensel; P Kraft; P G Steinherz; B Lange; R Hutchinson; G H Reaman; P S Gaynon; N A Heerema Journal: Leuk Lymphoma Date: 1999-03
Authors: Kirk R Schultz; D Jeanette Pullen; Harland N Sather; Jonathan J Shuster; Meenakshi Devidas; Michael J Borowitz; Andrew J Carroll; Nyla A Heerema; Jeffrey E Rubnitz; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; Stephen P Hunger; William L Carroll; Paul S Gaynon; Bruce M Camitta Journal: Blood Date: 2006-09-26 Impact factor: 22.113
Authors: Nita L Seibel; Peter G Steinherz; Harland N Sather; James B Nachman; Cynthia Delaat; Lawrence J Ettinger; David R Freyer; Leonard A Mattano; Caroline A Hastings; Charles M Rubin; Kathy Bertolone; Janet L Franklin; Nyla A Heerema; Torrey L Mitchell; Allan F Pyesmany; Mei K La; Cheryl Edens; Paul S Gaynon Journal: Blood Date: 2007-11-26 Impact factor: 22.113
Authors: F M Uckun; W Jaszcz; J L Ambrus; A S Fauci; K Gajl-Peczalska; C W Song; M R Wick; D E Myers; K Waddick; J A Ledbetter Journal: Blood Date: 1988-01 Impact factor: 22.113
Authors: K G Waddick; D E Myers; R Gunther; L M Chelstrom; M Chandan-Langlie; J D Irvin; N Tumer; F M Uckun Journal: Blood Date: 1995-12-01 Impact factor: 22.113